MBX Biosciences, Inc. 8-K

What Happened
MBX Biosciences (MBX) filed a Form 8‑K (furnished Jan 12, 2026) disclosing its preliminary, unaudited cash, cash equivalents and marketable securities of $373.7 million as of December 31, 2025, and said that amount is expected to fund operations into 2029 under its current plan. On January 11, 2026 the company issued a press release (furnished as Exhibit 99.1) announcing a 2026 outlook and business update to be presented at the 44th Annual J.P. Morgan Healthcare Conference.

Key Details

• $373.7 million in unaudited cash, cash equivalents and marketable securities as of 12/31/2025.
• Company expects those funds to support operations into 2029 based on current operating plan.
• Plans to expand its obesity portfolio with two additional obesity candidates; nominations anticipated in Q2 and Q3 2026.
• Disclosures include standard forward‑looking statement warnings and note the estimate could change (final audited results or other developments may differ).

Why It Matters
For investors, the cash balance and runway estimate are the most material takeaways: MBX reports a multi‑year cash runway under current plans, which affects expectations for dilution, fundraising needs, and timing of R&D programs. The announced intention to nominate two more obesity candidates signals continued pipeline expansion and strategic focus on obesity programs. Note these are preliminary, unaudited figures and forward‑looking statements subject to risks and uncertainties described in the filing.